EnChannel Medical Announces Closing of Series A Financing to Develop Next Generation Cardiac Arrhythmia Mapping System and Pulsed Field Ablation Technology
- Oversubscribed financing round raised $27 million to support development and registration of novel mapping and ablation systems to treat complex cardiac arrhythmias.
Irvine, CA, August 1, 2023 – EnChannel Medical, a pioneering cardiac technology company dedicated to the development of critically needed diagnostic and therapeutic solutions for individualizing treatment for patients with complex cardiac arrhythmias, announced the recent closing of a $27 million Series A round of financing.
Co-led by LAV and Lapam Capital, this substantial investment will propel the company’s mission to transform the field of cardiac electrophysiology. The funds will be utilized to accelerate the development of their flagship products, facilitate clinical trials, and obtain regulatory approvals.
EnChannel Medical’s products include the DePolar® Arrhythmia Mapping System, a third-generation, state-of-the-art arrhythmia mapping platform that promises improved accuracy via hybrid magnetic and impedance navigation plus seamless integration of contact and non-contact mapping. In parallel with the arrhythmia mapping system, EnChannel is also developing a pulsed field ablation (PFA) therapy system which includes the NanoAblate™ PFA Generator and PFBasket® and PFLine® ablation catheters. When used together, these products enable personalized atrial fibrillation (AF) treatment through precise identification and non-thermal destruction of the sources responsible for both regular and irregular cardiac arrhythmias.
Feng Jun, CEO, and co-founder of EnChannel Medical, emphasized the significance of their approach, stating: “PFA has demonstrated an acceptable safety profile and faster procedure times than RF and cryoablation, however, outcomes have not improved. We believe that accurately mapping the substrate and locating the initiators and maintainers of the arrhythmia is the key to individualized treatment and improved outcomes.”
Mr. Yu Zhihua, founding partner of Lapam Capital, highlighted the broader impact of EnChannel’s advances, saying: “AF is a global epidemic, but the underlying mechanisms remain unclear and clinical treatment is largely empiric. The innovative, whole-chamber, arrhythmia mapping and ablation system being developed by EnChannel Medical is expected to reveal the arrhythmia mechanism, change treatment strategies, and improve patient outcomes.”
About Complex Cardiac Arrhythmias
Complex cardiac arrhythmias, such as AF and ventricular tachycardia, affect 2% of the general population. They are associated with significant morbidity, mortality, and annual healthcare costs exceeding $26B in the US.
About EnChannel Medical
Founded in 2020 by medical and industry experts in electrophysiology, EnChannel Medical is a pioneering cardiac technology company with headquarters in Guangzhou, China and a subsidiary in Irvine, CA. The company’s global team is committed to developing intuitive, safer, and more effective personalized solutions to assist electrophysiologists in treating patients with complex cardiac arrhythmias. For more information, please visit the company’s website at www.enchannel.com.
About Lapam Capital
Lapam Capital is a leading Chinese biopharmaceutical venture capital firm headquartered in Beijing, China. Specializing in investments in innovative drugs and medical devices being developed by start-up and early-to mid-stage companies.
About LAV
LAV is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong and Menlo Park. Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.